Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,763
archived clinical trials in
Colitis

Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated:  6/19/2013
Santarus Clinical Investigational Site 1067
mi
from
Lake Success, NY
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated: 6/19/2013
Santarus Clinical Investigational Site 1067
mi
from
Lake Success, NY
Click here to add this to my saved trials
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated:  6/19/2013
Santarus Clinical Investigational Site 1031
mi
from
New York, NY
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated: 6/19/2013
Santarus Clinical Investigational Site 1031
mi
from
New York, NY
Click here to add this to my saved trials
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated:  6/19/2013
Santarus Clinical Investigational Site 1040
mi
from
Boone, NC
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated: 6/19/2013
Santarus Clinical Investigational Site 1040
mi
from
Boone, NC
Click here to add this to my saved trials
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated:  6/19/2013
Santarus Clinical Investigational Site 1073
mi
from
Wilmington, NC
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated: 6/19/2013
Santarus Clinical Investigational Site 1073
mi
from
Wilmington, NC
Click here to add this to my saved trials
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated:  6/19/2013
Santarus Clinical Investigational Site 1080
mi
from
Cincinati, OH
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated: 6/19/2013
Santarus Clinical Investigational Site 1080
mi
from
Cincinati, OH
Click here to add this to my saved trials
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated:  6/19/2013
Santarus Clinical Investigational Site 1078
mi
from
Cleveland, OH
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated: 6/19/2013
Santarus Clinical Investigational Site 1078
mi
from
Cleveland, OH
Click here to add this to my saved trials
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated:  6/19/2013
Santarus Clinical Investigational Site 1082
mi
from
Dayton, OH
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated: 6/19/2013
Santarus Clinical Investigational Site 1082
mi
from
Dayton, OH
Click here to add this to my saved trials
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated:  6/19/2013
Santarus Clinical Investigational Site 1017
mi
from
Mentor, OH
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated: 6/19/2013
Santarus Clinical Investigational Site 1017
mi
from
Mentor, OH
Click here to add this to my saved trials
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated:  6/19/2013
Santarus Clinical Investigational Site 1064
mi
from
Lancaster, PA
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated: 6/19/2013
Santarus Clinical Investigational Site 1064
mi
from
Lancaster, PA
Click here to add this to my saved trials
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated:  6/19/2013
Santarus Clinical Investigational Site 1066
mi
from
Sayre, PA
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated: 6/19/2013
Santarus Clinical Investigational Site 1066
mi
from
Sayre, PA
Click here to add this to my saved trials
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated:  6/19/2013
Santarus Clinical Investigational Site 1059
mi
from
Austin, TX
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated: 6/19/2013
Santarus Clinical Investigational Site 1059
mi
from
Austin, TX
Click here to add this to my saved trials
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated:  6/19/2013
Santarus Clinical Investigational Site 1019
mi
from
Houston, TX
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated: 6/19/2013
Santarus Clinical Investigational Site 1019
mi
from
Houston, TX
Click here to add this to my saved trials
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated:  6/19/2013
Santarus Clinical Investigational Site 1004
mi
from
Houston, TX
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated: 6/19/2013
Santarus Clinical Investigational Site 1004
mi
from
Houston, TX
Click here to add this to my saved trials
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated:  6/19/2013
Santarus Clinical Investigational Site 1005
mi
from
Pasadena, TX
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated: 6/19/2013
Santarus Clinical Investigational Site 1005
mi
from
Pasadena, TX
Click here to add this to my saved trials
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated:  6/19/2013
Santarus Clinical Investigational Site 1048
mi
from
The Woodlands, TX
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated: 6/19/2013
Santarus Clinical Investigational Site 1048
mi
from
The Woodlands, TX
Click here to add this to my saved trials
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated:  6/19/2013
Santarus Clinical Investigational Site 1014
mi
from
Lancaster, UT
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated: 6/19/2013
Santarus Clinical Investigational Site 1014
mi
from
Lancaster, UT
Click here to add this to my saved trials
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated:  6/19/2013
Santarus Clinical Investigational Site 1020
mi
from
Ogden, UT
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated: 6/19/2013
Santarus Clinical Investigational Site 1020
mi
from
Ogden, UT
Click here to add this to my saved trials
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated:  6/19/2013
Santarus Clinical Investigational Site 1038
mi
from
Chesapeake, VA
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated: 6/19/2013
Santarus Clinical Investigational Site 1038
mi
from
Chesapeake, VA
Click here to add this to my saved trials
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated:  6/19/2013
Santarus Clinical Investigational Site 1025
mi
from
Christianburg, VA
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated: 6/19/2013
Santarus Clinical Investigational Site 1025
mi
from
Christianburg, VA
Click here to add this to my saved trials
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated:  6/19/2013
Santarus Clinical Investigational Site 1007
mi
from
Richmond, VA
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated: 6/19/2013
Santarus Clinical Investigational Site 1007
mi
from
Richmond, VA
Click here to add this to my saved trials
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated:  6/19/2013
Santarus Clinical Investigational Site 1036
mi
from
Madison, WI
Randomized Placebo Controlled Trial of Budesonide MMX® 9 mg in Patients With Ulcerative Colitis Currently on a 5-ASA
Status: Enrolling
Updated: 6/19/2013
Santarus Clinical Investigational Site 1036
mi
from
Madison, WI
Click here to add this to my saved trials
Effects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease Activity
Effects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease Activity
Status: Enrolling
Updated:  8/6/2013
University of Illinois at Chicago
mi
from
Chicago, IL
Effects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease Activity
Effects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease Activity
Status: Enrolling
Updated: 8/6/2013
University of Illinois at Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Effects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease Activity
Effects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease Activity
Status: Enrolling
Updated:  8/6/2013
University of Chicago
mi
from
Chicago, IL
Effects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease Activity
Effects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease Activity
Status: Enrolling
Updated: 8/6/2013
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
IRT in Infants With Intestinal Perforation
Immunoreactive Trypsinogen in Infants With Intestinal Perforation
Status: Enrolling
Updated:  8/7/2013
Childrens Hospitals And Clinics Of Minnesota
mi
from
St. Paul, MN
IRT in Infants With Intestinal Perforation
Immunoreactive Trypsinogen in Infants With Intestinal Perforation
Status: Enrolling
Updated: 8/7/2013
Childrens Hospitals And Clinics Of Minnesota
mi
from
St. Paul, MN
Click here to add this to my saved trials
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated:  9/25/2013
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated: 9/25/2013
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
Click here to add this to my saved trials
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated:  9/25/2013
Rocky Mountain Gastroenterology Associates
mi
from
Thornton, CO
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated: 9/25/2013
Rocky Mountain Gastroenterology Associates
mi
from
Thornton, CO
Click here to add this to my saved trials
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated:  9/25/2013
Shafran Gastroenterology Center
mi
from
Winter Park, FL
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated: 9/25/2013
Shafran Gastroenterology Center
mi
from
Winter Park, FL
Click here to add this to my saved trials
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated:  9/25/2013
Chevy Chase Clinical Research
mi
from
Chevy Chase, MD
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated: 9/25/2013
Chevy Chase Clinical Research
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated:  9/25/2013
Clinical Research Institute of Michigan, LLC
mi
from
Chesterfield, MI
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated: 9/25/2013
Clinical Research Institute of Michigan, LLC
mi
from
Chesterfield, MI
Click here to add this to my saved trials
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated:  9/25/2013
Center for Digestive & Liver Disease, Inc.
mi
from
Mexico, MO
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated: 9/25/2013
Center for Digestive & Liver Disease, Inc.
mi
from
Mexico, MO
Click here to add this to my saved trials
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated:  9/25/2013
Remington Davis Inc.
mi
from
Columbus, OH
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated: 9/25/2013
Remington Davis Inc.
mi
from
Columbus, OH
Click here to add this to my saved trials
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated:  9/25/2013
Oklahoma Foundation for Digestive Research
mi
from
Oklahoma City, OK
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated: 9/25/2013
Oklahoma Foundation for Digestive Research
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated:  9/25/2013
Nashville Medical Research Institute
mi
from
Nashville, TN
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis
Status: Enrolling
Updated: 9/25/2013
Nashville Medical Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Fecal Microbiota Therapy for Recurrent Clostridium Difficile Colitis
Fecal Microbiota Therapy for Recurrent Clostridium Difficile Colitis
Status: Enrolling
Updated:  10/25/2013
OSF Saint Francis Medical Center
mi
from
Peoria, IL
Fecal Microbiota Therapy for Recurrent Clostridium Difficile Colitis
Fecal Microbiota Therapy for Recurrent Clostridium Difficile Colitis
Status: Enrolling
Updated: 10/25/2013
OSF Saint Francis Medical Center
mi
from
Peoria, IL
Click here to add this to my saved trials
Efficacy of Gralise® for Chronic Pelvic Pain
Efficacy of Gralise® for Chronic Pelvic Pain
Status: Enrolling
Updated:  10/29/2013
Rehabilitation Institute of Chicago
mi
from
Chicago, IL
Efficacy of Gralise® for Chronic Pelvic Pain
Efficacy of Gralise® for Chronic Pelvic Pain
Status: Enrolling
Updated: 10/29/2013
Rehabilitation Institute of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
General Surgical Outcomes Quality Improvement Database (UH-SOCRATES)
General Surgical Outcomes Quality Improvement Database (UH-SOCRATES)
Status: Enrolling
Updated:  12/11/2013
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
General Surgical Outcomes Quality Improvement Database (UH-SOCRATES)
General Surgical Outcomes Quality Improvement Database (UH-SOCRATES)
Status: Enrolling
Updated: 12/11/2013
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/14/2014
Clinical Research Facility
mi
from
Birmingham, AL
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/14/2014
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/14/2014
Clinical Research Facility
mi
from
Little Rock, AR
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/14/2014
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/14/2014
Clinical Research Facility
mi
from
Roseville, CA
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/14/2014
Clinical Research Facility
mi
from
Roseville, CA
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/14/2014
Clinical Research Facility
mi
from
San Diego, CA
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/14/2014
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/14/2014
Clinical Research Facility
mi
from
Golden, CO
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/14/2014
Clinical Research Facility
mi
from
Golden, CO
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/14/2014
Clinical Research Facility
mi
from
Newark, DE
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/14/2014
Clinical Research Facility
mi
from
Newark, DE
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/14/2014
Clinical Research Facility
mi
from
Boca Raton, FL
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/14/2014
Clinical Research Facility
mi
from
Boca Raton, FL
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/14/2014
Clinical Research Facility
mi
from
Gainesville, FL
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/14/2014
Clinical Research Facility
mi
from
Gainesville, FL
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/14/2014
Clinical Research Facility
mi
from
Hialeah, FL
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/14/2014
Clinical Research Facility
mi
from
Hialeah, FL
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/14/2014
Clinical Research Facility
mi
from
Naples, FL
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/14/2014
Clinical Research Facility
mi
from
Naples, FL
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/14/2014
Clinical Research Facility
mi
from
New Port Richey, FL
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/14/2014
Clinical Research Facility
mi
from
New Port Richey, FL
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/14/2014
Clinical Research Facility
mi
from
Port Orange, FL
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/14/2014
Clinical Research Facility
mi
from
Port Orange, FL
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/14/2014
Clinical Research Facility
mi
from
Winter Park, FL
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/14/2014
Clinical Research Facility
mi
from
Winter Park, FL
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/14/2014
Clinical Research Facility
mi
from
Zephyrhills, FL
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/14/2014
Clinical Research Facility
mi
from
Zephyrhills, FL
Click here to add this to my saved trials